2026年10月27日，Anthropic发布其生命科学计划概览，详述了与六家机构的深度研究合作伙伴关系：BigHat Biosciences、百时美施贵宝、Divergence Labs、Enveda、Generate Biomedicines和The Column Group。
Anthropic Details Preclinical Drug Discovery Collaborations and Mithril Medicine Acquisition On October 27, 2026, Anthropic published an overview of its life sciences initiatives, detailing deep research partnerships with six organizations: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group.
这些计划利用Claude加速药物开发任务，涵盖抗体设计、先导化合物优化、CAR T细胞工程、监管文档编制和临床试验规划。
The initiatives utilize Claude to accelerate drug development tasks spanning antibody design, lead optimization, CAR T-cell engineering, regulatory documentation, and clinical trial planning.
Anthropic还宣布收购Mithril Medicine，以开发针对罕见肌营养不良症的内部疗法，同时推出Claude Science和生命科学验证计划，扩大研究人员对其模型的使用权限。
Anthropic also announced the acquisition of Mithril Medicine to pursue internal treatments for rare muscular dystrophy, alongside the rollout of Claude Science and the Life Sciences Verification Program to broaden researcher access to its models.